Pharmacogenetic variants in pharmacokinetic and pharmacodynamic pathways and clinical factors associated with bleeding risk in Thai patients receiving rivaroxaban: a case–control study
Therapeutic Advances in Drug Safety · 2026-05 · 17
DOI: 10.1177/20420986261452545 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Advances in Drug Safety, online erschienen am 29.05.2026. Verfasst von Varalee Yodsurang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Physiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: The Faculty of Pharmaceutical Sciences Fund, Chulalongkorn University, The Ratchadaphiseksomphot Endowment Fund, Chulalongkorn University.
Abstract (Originalsprache)
Background
While bleeding is an inherent risk of all anticoagulant therapies, individual susceptibility varies considerably. Rivaroxaban, a direct oral anticoagulant widely used for thromboembolic prevention, is associated with substantial interindividual variability in bleeding risk, posing an ongoing clinical challenge.
Objectives
To investigate associations between pharmacogenetic variants in five pharmacokinetic (PK) and nine pharmacodynamic (PD) genes, along with clinical factors, and bleeding outcomes in Thai patients receiving rivaroxaban.
Design
A retrospective case–control study was conducted among 91 patients with atrial fibrillation, including 27 who experienced bleeding events.
Methods
Genetic variants in PK and PD genes were genotyped using the MassARRAY ® system, and associations between pharmacogenetic variants, clinical factors, and bleeding risk were evaluated using logistic regression analysis.
Results
The CT genotype of ABCB1 rs10276036 (C>T) was associated with an increased risk of bleeding. Clinical factors, including prior bleeding history, were also significantly associated with increased bleeding risk. In addition, allele frequency patterns suggested population-specific genetic variation in this Thai cohort. These findings suggest that genetic and clinical factors may jointly contribute to bleeding susceptibility.
Conclusion
Bleeding risk in Thai patients receiving rivaroxaban appeared to be influenced by both pharmacogenetic variants, particularly the ABCB1 rs10276036, and established clinical factors. These findings are exploratory and highlight the potential value of integrating genetic and clinical information for risk stratification, pending validation in larger cohorts.
Trial registration
As a retrospective non-interventional study, this work was not registered in a clinical trial registry. Ethical approval was obtained (COA No. 1657/2022).
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacology and Physiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand.
- Center of Excellence in Preclinical Toxicity and Efficacy Assessment of Medicines and Chemicals, Chulalongkorn University, Bangkok, Thailand.
- Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand.
- Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand.
- Division of Cardiovascular Medicine, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
- Cardiac Center, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand.
ORCID-Profile: Varalee Yodsurang, Krit Wattanathum, Thanate Srimatimanon, Krittin Pitinanon, Andro Ranti, Pattaraporn Siripattarachai, Piyapha Hirunpatrawong, Voravut Rungpradubvong, Seiichi Sakamoto, Alisara Sangviroon Sujarit
Förderung
- The Faculty of Pharmaceutical Sciences Fund, Chulalongkorn University
- The Ratchadaphiseksomphot Endowment Fund, Chulalongkorn University
Zitieren
APA
Yodsurang, V., Wattanathum, K., Srimatimanon, T., Pitinanon, K., Ranti, A., Siripattarachai, P., Hirunpatrawong, P., Rungpradubvong, V., Sakamoto, S., & Sujarit, A. S. (2026). Pharmacogenetic variants in pharmacokinetic and pharmacodynamic pathways and clinical factors associated with bleeding risk in Thai patients receiving rivaroxaban: a case–control study. Therapeutic Advances in Drug Safety, 17. https://doi.org/10.1177/20420986261452545
Vancouver
Yodsurang V, Wattanathum K, Srimatimanon T, Pitinanon K, Ranti A, Siripattarachai P, et al. Pharmacogenetic variants in pharmacokinetic and pharmacodynamic pathways and clinical factors associated with bleeding risk in Thai patients receiving rivaroxaban: a case–control study. Therapeutic Advances in Drug Safety. 2026;17. doi:10.1177/20420986261452545
BibTeX
@article{Yodsurang2026,
author = {Yodsurang, Varalee and Wattanathum, Krit and Srimatimanon, Thanate and Pitinanon, Krittin and Ranti, Andro and Siripattarachai, Pattaraporn and Hirunpatrawong, Piyapha and Rungpradubvong, Voravut and Sakamoto, Seiichi and Sujarit, Alisara Sangviroon},
title = {Pharmacogenetic variants in pharmacokinetic and pharmacodynamic pathways and clinical factors associated with bleeding risk in Thai patients receiving rivaroxaban: a case–control study},
journal = {Therapeutic Advances in Drug Safety},
year = {2026},
volume = {17},
doi = {10.1177/20420986261452545}
}
EUVIMED